首页> 美国卫生研究院文献>British Journal of Cancer >A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.
【2h】

A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.

机译:小细胞肺癌中计划化疗和根据需要化疗的随机试验:一项癌症研究运动试验。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In a study of chemotherapy as palliative treatment, 300 patients with untreated limited and extensive stage small cell lung cancer (SCLC), who did not have progressive disease after the first cycle of chemotherapy, were randomised to receive either regular 'planned' chemotherapy or chemotherapy given 'as required' (AR). All patients received the same chemotherapy: cyclophosphamide 1 gm m-2 i.v., vincristine 2 mg i.v., and etoposide 120 mg m-2 i.v. on day 1, and etoposide 100 mg b.d. orally on days 2 and 3. Planned chemotherapy was given regularly every 3 weeks. AR chemotherapy was given for tumour-related symptoms, or for radiological progression of disease. Both groups of patients were assessed every 3 weeks and a maximum of eight cycles of chemotherapy was given. A detailed quality of life assessment was made using daily diary cards. The median survival (MS) of patients given AR chemotherapy was not significantly worse than those receiving planned treatment [MS: Planned = 36 weeks (95% C.I. 32-40 weeks), AR = 32 weeks (95% C.I. 28-37 weeks) P = 0.960]. In the AR patients the median interval between treatments was 42 days. On average AR patients received half as much chemotherapy as planned patients. AR patients with a treatment-free interval (TFI) of more than 8 weeks between the first and second cycles of chemotherapy survived longer than those in whom this interval was less than 4 weeks; [MS: TFI greater than 8 = 47 weeks (95% C.I. 32-53 weeks); TFI less than 4 = 24 weeks (95% C.I. 17-34 weeks) P = 0.013]. Contrary to expectation, in the quality of life assessment the AR patients scored themselves as having more severe symptoms than patients receiving planned treatment. AR chemotherapy is a novel method of attempting to use cytotoxic drugs palliatively, which resulted in less drug treatment for approximately equivalent survival. However the palliative effect seen with as required treatment was less satisfactory than with planned chemotherapy.
机译:在一项关于化疗作为姑息治疗的研究中,将300例未经治疗的局限性和广泛分期的小细胞肺癌(SCLC)的患者在第一轮化疗后均无进展性疾病,被随机分配接受常规“计划”化疗或化疗给予“按要求”(AR)。所有患者均接受相同的化疗:环磷酰胺1 gm m-2静脉内,长春新碱2 mg静脉内和依托泊苷120 mg m-2静脉内。第1天服用依托泊苷100毫克/天在第2天和第3天口服。每3周定期进行计划的化疗。因肿瘤相关症状或疾病的放射学进展而给予了AR化疗。两组患者每3周进行一次评估,最多进行8个化疗周期。使用每日日记卡进行了详细的生活质量评估。接受AR化疗的患者的中位生存期(MS)并不比接受计划治疗的患者明显差[MS:计划= 36周(95%CI 32-40周),AR = 32周(95%CI 28-37周) P = 0.960]。在AR患者中,两次治疗之间的平均间隔为42天。平均而言,AR患者接受的化疗是计划患者的一半。在第一轮和第二轮化疗之间,无治疗间隔(TFI)超过8周的AR患者的生存期比间隔少于4周的AR患者长。 [MS:TFI大于8 = 47周(95%C.I. 32-53周); TFI小于4 = 24周(95%C.I. 17-34周),P = 0.013]。与预期相反,在生活质量评估中,AR患者认为自己的症状比接受计划治疗的患者更为严重。 AR化学疗法是尝试姑息使用细胞毒性药物的新方法,其导致较少的药物治疗而获得大致相等的存活率。但是,所需治疗所见的姑息作用不如计划化疗满意。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号